Organovo Highlights FXR314 Near Term Value Catalysts at Jones Trading Conference Strong Preclinical and Human Rationale for FXR314 in P2 2 Ulcerative Colitis
16 juil. 2024 08h05 HE
|
Organovo, Inc.
Organovo presented on the Company’s near and long-term outlook, operational plans, at the Jones Trading Healthcare Conference in Encinitas, CA.
Biora Therapeutics to Host Virtual KOL Event on NaviCap™ Targeted Oral Delivery Platform and Results from Phase 1 Clinical Trial of BT-600 on July 17, 2024
08 juil. 2024 08h00 HE
|
Biora Therapeutics, Inc.
Event to highlight results from the clinical trial of BT-600, an orally administered drug-device combination in development for ulcerative colitis.
Biora Therapeutics Announces Positive Clinical Trial Results for BT-600
01 juil. 2024 08h00 HE
|
Biora Therapeutics, Inc.
BT-600 was well tolerated and met all trial objectives, demonstrating the NaviCap platform’s ability to deliver therapeutics directly to the colon
Morphic Demonstrates Novel Real-Time Visualization of Small Molecule α4β7 Inhibition of Gut-Trafficking Cells
21 mai 2024 08h00 HE
|
Morphic Therapeutic
in vivo video presented at DDW 2024 show small molecule α4β7 inhibition rapidly increases rolling velocity & flux of B cells similar to antibodies
Biora Therapeutics Presents Clinical Data on Device Function of the NaviCap™ Platform at Digestive Disease Week 2024
20 mai 2024 08h00 HE
|
Biora Therapeutics, Inc.
Four device performance studies demonstrate the NaviCap platform’s ability to deliver therapeutics directly to the colon under variable GI conditions.
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024
08 mai 2024 02h30 HE
|
Abivax
Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and preclinical colon cancer model at Digestive Disease Week 2024 PARIS, France, May 8, 2024, 8:30 a.m. CEST –...
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
04 avr. 2024 08h00 HE
|
Biora Therapeutics, Inc.
All pharmacokinetic endpoints were achieved; all NaviCap™ devices performed as intended; no safety signals observed
Abivax reports 2023 financial results and operational update
02 avr. 2024 02h30 HE
|
Abivax
Abivax reports 2023 financial results and operational update Raised EUR 500M in 2023, including a EUR 130M capital increase, two structured debt financing transactions aggregating EUR 150M and...
Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease
20 mars 2024 20h05 HE
|
Sosei Group Corporation
HTL0033744 has been designed by Sosei Heptares to promote mucosal healing and resolve inflammation in people with IBD Tokyo, Japan and Cambridge, UK, 21 March 2024 – Sosei Group Corporation (“Sosei...
Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease
20 mars 2024 20h01 HE
|
Sosei Group Corporation
GPR35 is a novel target with an established genetic association to IBDUK regulatory approval received to commence first-in-human studiesReturn of rights follows change in immunology research strategy...